Chudi Ndubaku

Employment

• Paraza Pharma (Canada)

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (33)

• NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists
  Science Immunology 2020 DOI: 10.1126/sciimmunol.aaz2738
  +Save
• Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
  Journal of Medicinal Chemistry 2019 DOI: 10.1021/acs.jmedchem.9b00439
  +Save
• Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol
  Chemical Science 2019 DOI: 10.1039/c9sc02572c
  +Save
• Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
  Cell Reports 2018 DOI: 10.1016/j.celrep.2018.11.047
  +Save
• Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques
  Journal of Medicinal Chemistry 2017 DOI: 10.1021/acs.jmedchem.7b01293
  +Save
• USP7 small-molecule inhibitors interfere with ubiquitin binding
  Nature 2017 DOI: 10.1038/nature24006
  +Save
• Abstract B020: STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent antitumor immunity
  Cancer Immunology Research 2016 DOI: 10.1158/2326-6066.imm2016-b020
  +Save
• Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity
  Cancer Research 2016 DOI: 10.1158/1538-7445.am2016-1445
  +Save
• Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
  Cancer Research 2016 DOI: 10.1158/1538-7445.am2016-sy39-02
  +Save
• Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window
  Journal of Medicinal Chemistry 2016 DOI: 10.1021/acs.jmedchem.6b00638
  +Save